|  Help  |  About  |  Contact Us

Publication : Nox1 NADPH oxidase is necessary for late but not early myocardial ischaemic preconditioning.

First Author  Jiang S Year  2014
Journal  Cardiovasc Res Volume  102
Issue  1 Pages  79-87
PubMed ID  24501329 Mgi Jnum  J:229347
Mgi Id  MGI:5751652 Doi  10.1093/cvr/cvu027
Citation  Jiang S, et al. (2014) Nox1 NADPH oxidase is necessary for late but not early myocardial ischaemic preconditioning. Cardiovasc Res 102(1):79-87
abstractText  AIMS: Ischaemic preconditioning (IPC) is an adaptive mechanism that renders the myocardium resistant to injury from subsequent hypoxia. Although reactive oxygen species (ROS) contribute to both the early and late phases of IPC, their enzymatic source and associated signalling events have not yet been understood completely. Our objective was to investigate the role of the Nox1 NADPH oxidase in cardioprotection provided by IPC. METHODS AND RESULTS: Wild-type (WT) and Nox1-deficient mice were treated with three cycles of brief coronary occlusion and reperfusion, followed by prolonged occlusion either immediately (early IPC) or after 24 h (late IPC). Nox1 deficiency had no impact on the cardioprotection afforded by early IPC. In contrast, deficiency of Nox1 during late IPC resulted in a larger infarct size, cardiac remodelling, and increased myocardial apoptosis compared with WT hearts. Furthermore, expression of Nox1 in WT hearts increased in response to late IPC. Deficiency of Nox1 abrogated late IPC-mediated activation of cardiac nuclear factor-kappaB (NF-kappaB) and induction of tumour necrosis factor-alpha (TNF-alpha) in the heart and circulation. Finally, knockdown of Nox1 in cultured cardiomyocytes prevented TNF-alpha induction of NF-kappaB and the protective effect of IPC on hypoxia-induced apoptosis. CONCLUSIONS: Our data identify a critical role for Nox1 in late IPC and define a previously unrecognized link between TNF-alpha and NF-kappaB in mediating tolerance to myocardial injury. These findings have clinical significance considering the emergence of Nox1 inhibitors for the treatment of cardiovascular disease.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

3 Bio Entities

0 Expression